Chemistry:MDX-1097
From HandWiki
Short description: Monoclonal antibody
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Clinical data | |
| Other names | IST-1097; KappaMab |
| Identifiers | |
| CAS Number | |
MDX-1097 (also called IST-1097 or KappaMab) is a monoclonal antibody therapy being assessed in Phase IIb clinical trials as a treatment for multiple myeloma, a type of white blood cell cancer.[1] It is a chimeric version of the mouse monoclonal antibody K-1-21.[2] MDX-1097 targets kappa free immunoglobulin light chains which are found on the surface of some kappa light chain-restricted myeloma cells.[3][4]
MDX-1097 was originally developed by scientists at Immune System Therapeutics Ltd.[4] In 2015, Haemalogix Pty Ltd acquired the rights to MDX-1097 and are now taking it through late stage clinical testing.[5][6]
References
- ↑ "Australian New Zealand Clinical Trials Registry Number 12616001164482". https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=371289.
- ↑ "Characterization of a unique conformational epitope on free immunoglobulin kappa light chains that is recognized by an antibody with therapeutic potential". Molecular Immunology 48 (9-10): 1245–1252. May 2011. doi:10.1016/j.molimm.2011.03.003. PMID 21466897.
- ↑ "Free Ig light chains interact with sphingomyelin and are found on the surface of myeloma plasma cells in an aggregated form". Journal of Immunology 185 (7): 4179–4188. October 2010. doi:10.4049/jimmunol.1001956. PMID 20817866.
- ↑ 4.0 4.1 "Preclinical and clinical development of an anti-kappa free light chain mAb for multiple myeloma". Molecular Immunology 67 (2 Pt A): 89–94. October 2015. doi:10.1016/j.molimm.2015.04.013. PMID 25964097.
- ↑ "Immune System Therapeutics Circular to Creditors 25 May 2015". https://www.mcgrathnicol.com/app/uploads/Circular-to-creditors-25-May-20151.pdf.
- ↑ "MDX-1097 Clinical Trials". Haemalogix Website. http://www.haemalogix.com/science/clinical-trials/5.
 |  |
